Logo
x

Search

Subscribe Now

 IgA Nephropathy

Renalys Pharma’s Sparsentan Secures the MHLW’s Orphan Drug Designation to Treat Primary IgA Nephropathy

Renalys Pharma’s Sparsentan Secures the MHLW’s Orphan Drug Designation to Treat Primary IgA Nephropathy

  • December 2, 2024
Jade Biosciences Reverse Merges with Aerovate Therapeutics to Advance Standard of Care for Autoimmune Diseases

Jade Biosciences Reverse Merges with Aerovate Therapeutics to Advance Standard of Care for Autoimmune Diseases

  • November 4, 2024
Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024

Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024

  • October 28, 2024
Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Full Approval for Treating IgA Nephropathy

Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Full Approval for Treating IgA Nephropathy

  • September 6, 2024
Novartis Reports the US FDA’s Accelerated Approval of Fabhalta to Treat Primary IgA Nephropathy (IgAN)

Novartis Reports the US FDA’s Accelerated Approval of Fabhalta to Treat Primary IgA Nephropathy (IgAN)

  • August 9, 2024
Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

  • May 27, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.